CY1121455T1 - Πολυπεπτιδια τα οποια δεσμευονται σε ανθρωπινη c5 συμπληρωματικου - Google Patents

Πολυπεπτιδια τα οποια δεσμευονται σε ανθρωπινη c5 συμπληρωματικου

Info

Publication number
CY1121455T1
CY1121455T1 CY20191100331T CY191100331T CY1121455T1 CY 1121455 T1 CY1121455 T1 CY 1121455T1 CY 20191100331 T CY20191100331 T CY 20191100331T CY 191100331 T CY191100331 T CY 191100331T CY 1121455 T1 CY1121455 T1 CY 1121455T1
Authority
CY
Cyprus
Prior art keywords
polypeptides
supplement
bound
human
treatment
Prior art date
Application number
CY20191100331T
Other languages
Greek (el)
English (en)
Inventor
Charlotta BERGHARD
Magnus Berglund
Patrik STRÖMBERG
Malin Lindborg
Elin Gunneriusson
Joachim Feldwisch
Original Assignee
Swedish Orphan Biovitrum Ab (Publ)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab (Publ) filed Critical Swedish Orphan Biovitrum Ab (Publ)
Publication of CY1121455T1 publication Critical patent/CY1121455T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
CY20191100331T 2012-02-20 2019-03-20 Πολυπεπτιδια τα οποια δεσμευονται σε ανθρωπινη c5 συμπληρωματικου CY1121455T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1250145 2012-02-20
PCT/SE2013/050139 WO2013126006A1 (en) 2012-02-20 2013-02-19 Polypeptides binding to human complement c5

Publications (1)

Publication Number Publication Date
CY1121455T1 true CY1121455T1 (el) 2020-05-29

Family

ID=49006055

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100331T CY1121455T1 (el) 2012-02-20 2019-03-20 Πολυπεπτιδια τα οποια δεσμευονται σε ανθρωπινη c5 συμπληρωματικου

Country Status (31)

Country Link
US (5) US9808502B2 (enExample)
EP (3) EP3511339B1 (enExample)
JP (2) JP6276202B2 (enExample)
KR (2) KR102336895B1 (enExample)
CN (1) CN104114574B (enExample)
AU (3) AU2013222836B2 (enExample)
BR (1) BR112014020427B1 (enExample)
CA (1) CA2863862C (enExample)
CY (1) CY1121455T1 (enExample)
DK (1) DK2817329T3 (enExample)
ES (1) ES2715638T3 (enExample)
HR (1) HRP20190522T1 (enExample)
HU (1) HUE041996T2 (enExample)
IL (2) IL234114B (enExample)
LT (1) LT2817329T (enExample)
ME (1) ME03640B (enExample)
MX (1) MX359201B (enExample)
MY (1) MY167232A (enExample)
NZ (1) NZ628625A (enExample)
PH (1) PH12014501604B1 (enExample)
PL (1) PL2817329T3 (enExample)
PT (1) PT2817329T (enExample)
RS (1) RS58503B1 (enExample)
RU (1) RU2654668C2 (enExample)
SG (1) SG11201404942UA (enExample)
SI (1) SI2817329T1 (enExample)
SM (1) SMT201900189T1 (enExample)
TR (1) TR201903840T4 (enExample)
UA (1) UA117096C2 (enExample)
WO (1) WO2013126006A1 (enExample)
ZA (1) ZA201406773B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2715638T3 (es) 2012-02-20 2019-06-05 Swedish Orphan Biovitrum Ab Publ Polipéptidos que se unen al complemento humano C5
CN104854127B (zh) 2012-10-25 2020-12-25 阿菲博迪公司 白蛋白结合多肽
JP6396303B2 (ja) 2012-10-25 2018-09-26 アフィボディ・アーベー アルブミン結合を含有するタンパク質の分離方法
EP3039033B1 (en) 2013-08-28 2019-06-19 Affibody AB Binding polypeptides having a mutated scaffold
SMT202100006T1 (it) * 2013-08-28 2021-03-15 Ipc Research Llc Polipeptidi stabili che si legano al complemento umano c5
ES2895029T3 (es) * 2014-06-12 2022-02-17 Ra Pharmaceuticals Inc Modulación de actividad del complemento
US10669314B2 (en) 2014-06-13 2020-06-02 Affibody Ab Polypeptide
JP6678661B2 (ja) 2014-06-13 2020-04-08 アフィボディ アクティエボラーグ 新規ポリペプチド
DE102014225439A1 (de) * 2014-12-10 2016-06-16 Zf Friedrichshafen Ag Stufenplanet
AU2016208161B2 (en) * 2015-01-12 2020-01-16 Affibody Ab IL-17A-binding polypeptides
RS62630B9 (sr) 2015-01-28 2022-04-29 Ra Pharmaceuticals Inc Modulatori aktivnosti komplementa
PL3685847T3 (pl) * 2015-12-16 2023-05-08 Ra Pharmaceuticals, Inc. Modulatory aktywności dopełniacza
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
UY37651A (es) 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
KR20250068795A (ko) * 2017-07-11 2025-05-16 알렉시온 파마슈티칼스, 인코포레이티드 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질
US20220205061A1 (en) 2019-04-03 2022-06-30 Clean Earth Technology Pty Ltd Materials and processes for recovering precious metals
WO2021089695A1 (en) * 2019-11-05 2021-05-14 Affibody Ab Polypeptides
CA3172994A1 (en) * 2020-10-05 2022-04-14 Paul P. Tamburini Methods of treating dermatomyositis
WO2024227886A1 (en) 2023-05-02 2024-11-07 Mebrahtu Aman Bispecific binding molecule

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
WO1995023512A1 (en) 1994-03-03 1995-09-08 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
CA2186108A1 (en) 1994-03-23 1995-09-28 Scott A. Rollins Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JP3971797B2 (ja) 1994-09-23 2007-09-05 アレクション・ファーマシューティカルズ・インク 炎症性関節疾患の治療方法
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
PT1325033E (pt) 2000-10-10 2010-04-15 Genentech Inc Inibição da activação do complemento c5 para o tratamento e a prevenção da rejeição diferida de um xenoenxertos ou de uma rejeição vascular aguda
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
ATE360441T1 (de) 2001-08-17 2007-05-15 Tanox Inc Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
ES2323692T3 (es) 2002-12-02 2009-07-23 Resistentia Holding Ab Metodos y materiales para tratar afecciones inflamatorias usando un polipeptido que comprende un segmento de aminoacidos c5 autogenicos y un segmento de aminoacidos no autogenicos.
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
WO2004106369A2 (en) 2003-06-02 2004-12-09 Evolutec Limited Complement inhibitors from ticks
CA2579635A1 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
SE0400274D0 (sv) 2004-02-09 2004-02-09 Affibody Ab New polypeptide
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
EP1735334A4 (en) 2004-03-24 2007-09-05 Auckland Uniservices Ltd SET1 PROTEINS AND APPLICATIONS THEREOF
US8642743B2 (en) 2004-04-06 2014-02-04 Affibody Ab Method for reducing the immune response to a biologically active protein
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
NZ567483A (en) * 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
GB0524788D0 (en) 2005-12-05 2006-01-11 Affibody Ab Polypeptides
CN104623692A (zh) 2006-03-08 2015-05-20 阿切埃米克斯股份有限公司 治疗视觉失调中使用的补体结合适体和抗-c5药物
AU2007225044C1 (en) 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
WO2008010902A2 (en) 2006-07-06 2008-01-24 The Trustees Of The University Of Pennsylvania Regulation of tlr signaling by complement
CA2662480C (en) 2006-09-05 2016-11-08 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
PE20081217A1 (es) * 2006-09-08 2008-09-24 Genentech Inc Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt
CN101679486A (zh) * 2007-03-22 2010-03-24 诺瓦提斯公司 C5抗原及其用途
US20100263061A1 (en) 2007-06-11 2010-10-14 The Trustees Of The University Of Pennsylvania Properdin Modulation of Alternative Pathway and Uses Thereof
ES2346178T3 (es) 2007-07-31 2015-11-02 Affibody Ab Nuevas composiciones, procedimientos y usos de unión de la albúmina
WO2009030240A2 (en) 2007-09-05 2009-03-12 Immunobond Aps Method of determining functional deficiencies in the complement system
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
US9187535B2 (en) * 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
PL2328616T3 (pl) 2008-08-05 2015-10-30 Novartis Ag Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5
BRPI0921237A2 (pt) 2008-11-10 2015-09-22 Alexion Pharma Inc métodos e composições para o tratamento de distúrbios associados ao complemento
EP2327725A1 (en) * 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
EP2542255B1 (en) 2010-03-01 2016-11-16 Alexion Pharmaceuticals, Inc. Compositions for treating degos' disease
US20110245469A1 (en) * 2010-04-02 2011-10-06 Athena Discovery, Inc. Intermediates formed in biosynthesis of relaxin-fusion proteins with extended in vivo half-lives
WO2011137395A1 (en) 2010-04-30 2011-11-03 Rother Russell P Anti-c5a antibodies and methods for using the antibodies
MX2013000314A (es) 2010-07-09 2013-01-29 Affibody Ab Polipeptidos.
ES2701075T3 (es) 2011-07-01 2019-02-20 Univ Pennsylvania Anticuerpos antiproperdina y usos de estos
ES2715638T3 (es) 2012-02-20 2019-06-05 Swedish Orphan Biovitrum Ab Publ Polipéptidos que se unen al complemento humano C5
WO2013172954A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
US9957330B2 (en) 2012-12-19 2018-05-01 Affibody Ab Polypeptides
KR102191654B1 (ko) 2013-03-15 2020-12-16 애피바디 에이비 신규 폴리펩티드
SMT202100006T1 (it) 2013-08-28 2021-03-15 Ipc Research Llc Polipeptidi stabili che si legano al complemento umano c5
EP3039033B1 (en) 2013-08-28 2019-06-19 Affibody AB Binding polypeptides having a mutated scaffold
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics

Also Published As

Publication number Publication date
PH12014501604A1 (en) 2014-10-08
RU2654668C2 (ru) 2018-05-21
HK1204790A1 (en) 2015-12-04
BR112014020427A8 (pt) 2018-01-23
EP3511339A1 (en) 2019-07-17
PL2817329T3 (pl) 2019-07-31
US20190167760A1 (en) 2019-06-06
PT2817329T (pt) 2019-04-01
CA2863862A1 (en) 2013-08-29
SG11201404942UA (en) 2014-09-26
EP2817329B1 (en) 2019-01-02
AU2019250239B2 (en) 2021-04-08
HRP20190522T1 (hr) 2019-05-03
MX359201B (es) 2018-09-19
BR112014020427B1 (pt) 2023-04-04
US9808502B2 (en) 2017-11-07
AU2013222836B2 (en) 2017-07-20
US20250332214A1 (en) 2025-10-30
EP3511339B1 (en) 2025-04-09
US11123401B2 (en) 2021-09-21
RS58503B1 (sr) 2019-04-30
JP2015508652A (ja) 2015-03-23
KR20200105953A (ko) 2020-09-09
CN104114574A (zh) 2014-10-22
WO2013126006A1 (en) 2013-08-29
LT2817329T (lt) 2019-04-10
US20150011474A1 (en) 2015-01-08
KR20140129163A (ko) 2014-11-06
PH12014501604B1 (en) 2018-11-07
AU2013222836A1 (en) 2014-09-18
US20210401930A1 (en) 2021-12-30
CN104114574B (zh) 2018-08-24
EP4616914A2 (en) 2025-09-17
EP2817329A1 (en) 2014-12-31
IL267724B (en) 2022-05-01
KR102149028B1 (ko) 2020-08-27
SMT201900189T1 (it) 2019-05-10
NZ628625A (en) 2016-03-31
JP2018052942A (ja) 2018-04-05
AU2017245376B2 (en) 2019-07-25
ZA201406773B (en) 2016-08-31
ME03640B (me) 2020-07-20
MX2014009879A (es) 2014-11-10
IL234114B (en) 2019-07-31
EP4616914A3 (en) 2025-11-19
US20180085428A1 (en) 2018-03-29
UA117096C2 (uk) 2018-06-25
AU2019250239A1 (en) 2019-11-07
JP6719438B2 (ja) 2020-07-08
RU2014137303A (ru) 2016-04-10
HUE041996T2 (hu) 2019-07-29
JP6276202B2 (ja) 2018-02-07
US12083160B2 (en) 2024-09-10
ES2715638T3 (es) 2019-06-05
SI2817329T1 (sl) 2019-04-30
DK2817329T3 (en) 2019-04-01
MY167232A (en) 2018-08-14
CA2863862C (en) 2021-03-16
US10206975B2 (en) 2019-02-19
KR102336895B1 (ko) 2021-12-08
EP2817329A4 (en) 2015-09-02
IL267724A (en) 2019-08-29
AU2017245376A1 (en) 2017-11-02
TR201903840T4 (tr) 2019-04-22

Similar Documents

Publication Publication Date Title
CY1121455T1 (el) Πολυπεπτιδια τα οποια δεσμευονται σε ανθρωπινη c5 συμπληρωματικου
CY1122107T1 (el) Τροποποιημενες πρωτεϊνες δεσμευσης οι οποιες αναστελλουν την αλληλεπιδραση υποδοχεα vegf-a
CY1124495T1 (el) Θεραπεια της amd με χρηση aav sflt-1
CY1119213T1 (el) Πρωτεϊνη p75ntr συνδεσης νευροτροφινης για θεραπευτικη χρηση
CY1124805T1 (el) Φλαγγελινη roseburia και ανοσοτροποποιηση
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
CY1122833T1 (el) Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
CY1119567T1 (el) Θεραπευτικα πεπτιδια
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1121736T1 (el) Άλατα aramchol
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
EA201792307A1 (ru) Способы репарации и регенерации тканей
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
CY1119030T1 (el) Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων
CY1121347T1 (el) Πρωτεϊνη συντηξης
MX2014003832A (es) Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo.
MX384191B (es) Molecula de union al antigeno especifico para el tejido objetivo.
IN2015MN00139A (enExample)
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
MX370924B (es) Composiciones para modular la expresión de c9orf72.
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
CY1125938T1 (el) Θεραπεια με βλαστοκυτταρα σε παθολογιες του ενδομητριου